Andere Sprachen Tevogen Bio Holdings Inc.

Aktien

A402TW

US88165K1016

TVGN

Markt geschlossen - Nasdaq Andere Börsenplätze 21:59:31 29.05.2024			% 5 Tage	% 1. Jan.
0,7724 ^USD	-2,65 %		-0,30 %	-93,06 %

13.05.	Anleger erwarten wichtige Inflationsdaten in den kommenden Tagen, US-Futures tendieren am Montag leicht höher	MT
13.05.	Top Premarket Gainers	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Tevogen Bio Reports First Quarter 2024 Financial Results	29.05.
Tevogen Bio Reports First Quarter 2024 Financial Results	29.05.
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives	16.05.
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday	13.05.
Top Premarket Gainers	13.05.
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives	10.05.
Tevogen Bio Holdings Inc. announced that it expects to receive $50 million in funding	10.05.
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives	01.05.
Sector Update: Health Care Stocks Higher in Afternoon Trading	26.04.
Tevogen Bio Shares Jump Following Report on $94.9 Million Liability Elimination	26.04.
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments	26.04.
Top Premarket Gainers	26.04.
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers	11.04.
Top Premarket Gainers	04.04.
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development	03.04.
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development	03.04.
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price	28.03.
Tevogen Bio Holdings Inc. amended terms of the transaction	27.03.
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant	20.03.
Tevogen Bio Holdings Announces TVGN 489, its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant	20.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Tevogen Bio Holdings Inc.

Aktien

A402TW

US88165K1016

TVGN

Andere Sprachen

Filter